Ignite Creation Date:
2025-12-24 @ 10:45 PM
Ignite Modification Date:
2025-12-25 @ 8:15 PM
Study NCT ID:
NCT01355835
Status:
COMPLETED
Last Update Posted:
2012-08-08
First Post:
2011-05-13
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Combined STN/SNr-DBS for the Treatment of Refractory Gait Disorders in Parkinson's Disease
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D010300', 'term': 'Parkinson Disease'}], 'ancestors': [{'id': 'D020734', 'term': 'Parkinsonian Disorders'}, {'id': 'D001480', 'term': 'Basal Ganglia Diseases'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D009069', 'term': 'Movement Disorders'}, {'id': 'D000080874', 'term': 'Synucleinopathies'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D046690', 'term': 'Deep Brain Stimulation'}], 'ancestors': [{'id': 'D004599', 'term': 'Electric Stimulation Therapy'}, {'id': 'D013812', 'term': 'Therapeutics'}, {'id': 'D013514', 'term': 'Surgical Procedures, Operative'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 12}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2011-02'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2012-08', 'completionDateStruct': {'date': '2012-08', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2012-08-07', 'studyFirstSubmitDate': '2011-05-13', 'studyFirstSubmitQcDate': '2011-05-17', 'lastUpdatePostDateStruct': {'date': '2012-08-08', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2011-05-18', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2012-08', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': "'Axial score'", 'timeFrame': 'Three weeks after active treatment (STN vs. STN+SNr), respectively', 'description': "The composite 'axial score' is built by 8 items from the UPDRS II and III, all 5-point rated (0 to 4) representing increasing levels of pathology. The 'axial score' will be scored by the sum of the ratings across the 8 items (Range 0 to 32). As change in UPDRS scores is a common primary efficacy outcome measure in Parkinson's disease and only items of the original UPDRS are required for the definition of the primary endpoint, the statistical evaluation methods should be based on the psychometric validation of the UPDRS and no own validation studies are necessary.\n\nSafety: falls"}], 'secondaryOutcomes': [{'measure': 'CAPSIT-PD', 'timeFrame': 'At baseline and three weeks after active treatment (STN vs. STN+SNr), respectively'}, {'measure': 'Freezing of gait assessment course', 'timeFrame': 'At baseline and three weeks after active treatment (STN vs. STN+SNr), respectively'}, {'measure': 'Freezing of gait questionnaire', 'timeFrame': 'At baseline and three weeks after active treatment (STN vs. STN+SNr), respectively'}, {'measure': 'Berg Balance Scale', 'timeFrame': 'At baseline and three weeks after active treatment (STN vs. STN+SNr), respectively'}, {'measure': 'Non-motor symptoms scale', 'timeFrame': 'At baseline and three weeks after active treatment (STN vs. STN+SNr), respectively'}, {'measure': 'Non-motor symptoms quest', 'timeFrame': 'At baseline and three weeks after active treatment (STN vs. STN+SNr), respectively'}, {'measure': "Beck's depression scale index", 'timeFrame': 'At baseline and three weeks after active treatment (STN vs. STN+SNr), respectively'}, {'measure': 'Minnesota Impulsive Disorders Interview', 'timeFrame': 'At baseline and three weeks after active treatment (STN vs. STN+SNr), respectively'}, {'measure': 'Barratt Impulsiveness Scale', 'timeFrame': 'At baseline and three weeks after active treatment (STN vs. STN+SNr), respectively'}, {'measure': 'UPDRS I-IV', 'timeFrame': 'At baseline and three weeks after active treatment (STN vs. STN+SNr), respectively'}, {'measure': 'PDQ-39', 'timeFrame': 'At baseline and three weeks after active treatment (STN vs. STN+SNr), respectively'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ["Parkinson's disease", 'gait', 'deep brain stimulation', 'substantia nigra pars reticulata', 'subthalamic nucleus'], 'conditions': ["Parkinson's Disease"]}, 'referencesModule': {'references': [{'pmid': '21287187', 'type': 'BACKGROUND', 'citation': "Weiss D, Breit S, Wachter T, Plewnia C, Gharabaghi A, Kruger R. Combined stimulation of the substantia nigra pars reticulata and the subthalamic nucleus is effective in hypokinetic gait disturbance in Parkinson's disease. J Neurol. 2011 Jun;258(6):1183-5. doi: 10.1007/s00415-011-5906-3. Epub 2011 Feb 2. No abstract available."}, {'pmid': '21989388', 'type': 'DERIVED', 'citation': "Weiss D, Wachter T, Meisner C, Fritz M, Gharabaghi A, Plewnia C, Breit S, Kruger R. Combined STN/SNr-DBS for the treatment of refractory gait disturbances in Parkinson's disease: study protocol for a randomized controlled trial. Trials. 2011 Oct 11;12:222. doi: 10.1186/1745-6215-12-222."}]}, 'descriptionModule': {'briefSummary': "12 patients with idiopathic Parkinson's disease and refractory gait disturbances under best individual subthalamic nucleus stimulation and dopaminergic medication will be included into this randomised double-blind cross-over two-armed clinical trial. The treatment consists of two different stimulation settings using (i) conventional stimulation of the subthalamic nucleus \\[STNmono\\] and (ii) combined stimulation of distant electrode contacts located in the subthalamic nucleus and caudal border zone of STN and substantia nigra pars reticulata \\[STN+SNr\\].", 'detailedDescription': "A composite 'axial score' including the major clinical and anamnestic items on gait, posture and balance function from UPDRSII (items 13-15) and UPDRS III (items 27-31) constitutes the primary outcome measure. Secondary outcome measures include specified clinical and anamnestic assessments on freezing of gait, balance, quality of life, non-motor symptoms, impulsivity, impulse control and neuropsychiatric symptoms. The aim of the present trial is to investigate the efficacy and safety of combined stimulation on subthalamic and nigral electrode contacts \\[STN+SNr\\] in refractory hypokinetic gait disturbances compared with \\[STNmono\\] (active comparator). The results will clarify, whether the combined \\[STN+SNr\\] stimulation improves otherwise refractory gait disturbances in PD."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Written informed consent\n* Age: between 18 and 80 years\n* Idiopathic Parkinson\'s disease (according to the "British Brain Bank criteria" (Hughes, 1992) including genetic forms and therapy with STN-DBS (ACTIVA pulse generators) at least six months from surgery\n* Optimized subthalamic stimulation at study enrolment (refer \'treatment\' section)\n* Gait disturbance refractory on best individual STN-DBS (STNmono) and dopaminergic therapy: \'gait score\' in the best clinical \\[MedOn/STNmono\\] condition ≥ 12\n* Clinical and image-guided (and facultatively electrophysiological) confirmation of (i) one of the two rostral contacts of the quadripolar electrode localized in the STN area, and (ii) the caudal contacts in the border zone of STN and SNr.\n* Dopaminergic medication constant for at least four weeks prior to study enrolment\n* Disease duration ≥ 5 years\n\nExclusion Criteria:\n\n* Cognitive impairment (Mini Mental State Exam \\< 25)\n* Participation in other clinical trials within the past three months and during enrolment in our study\n* Suicidality, Psychosis\n* Other severe pathological chronic condition that might confound treatment effects or interpretation of the data\n* Pregnancy\n* Acute adverse events from stimulation on contacts in the caudal STN / SNr border interfering with the intended stimulation protocol'}, 'identificationModule': {'nctId': 'NCT01355835', 'acronym': 'STN/SNr', 'briefTitle': "Combined STN/SNr-DBS for the Treatment of Refractory Gait Disorders in Parkinson's Disease", 'organization': {'class': 'OTHER', 'fullName': 'University Hospital Tuebingen'}, 'officialTitle': "Combined STN/SNr-DBS for the Treatment of Refractory Gait Disorders in Parkinson's Disease: Design of a Two-armed Double-blind Cross-over Study", 'orgStudyIdInfo': {'id': 'AKF 259-0-0'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': '[STNmono]', 'description': 'Conventional stimulation on subthalamic contacts', 'interventionNames': ['Device: deep brain stimulation (ACTIVA PC, Medtronic)']}, {'type': 'EXPERIMENTAL', 'label': '[STN+SNr]', 'description': 'Combined subthalamic and nigral stimulation', 'interventionNames': ['Device: deep brain stimulation (ACTIVA PC, Medtronic)']}], 'interventions': [{'name': 'deep brain stimulation (ACTIVA PC, Medtronic)', 'type': 'DEVICE', 'otherNames': ['Neurostimulation with ACTIVA PC, Medtronic'], 'description': 'High frequent deep brain stimulation with variable (best individual) stimulation on subthalamic contacts and standard parameters on nigral contacts (125 Hz, 60µs, best individual amplitude)', 'armGroupLabels': ['[STN+SNr]', '[STNmono]']}]}, 'contactsLocationsModule': {'locations': [{'zip': '72076', 'city': 'Tübingen', 'state': 'Baden-Wurttemberg', 'country': 'Germany', 'facility': 'Center of Neurology and Hertie Institute for Clinical Brain Research, and Department for Neurodegenerative Diseases, University of Tübingen', 'geoPoint': {'lat': 48.52266, 'lon': 9.05222}}], 'overallOfficials': [{'name': 'Daniel Weiss, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Center of Neurology and Hertie Institute for Clinical Brain Research, and Department for Neurodegenerative Diseases, University of Tübingen'}, {'name': 'Rejko Krüger, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Center of Neurology and Hertie Institute for Clinical Brain Research, and Department for Neurodegenerative Diseases, University of Tübingen'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University Hospital Tuebingen', 'class': 'OTHER'}, 'collaborators': [{'name': 'Medtronic', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'MD', 'investigatorFullName': 'Daniel Weiss', 'investigatorAffiliation': 'University Hospital Tuebingen'}}}}